Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma.
|Journal||Frontiers in Oncology|
|State||Published - 29 Sep 2022|
Bibliographical notePublisher Copyright:
Copyright © 2022 Renner, Rojas, Walton-Diaz and Burotto.
- renal cell carcinoma
- tyrosine kinase inhibitions (TKIs) therapy